Starting 2022 in earnest, Pfizer has agreed to collaborate with Beam Therapeutics to develop gene editing therapies for rare genetic diseases of the liver, muscle, and central nervous system. With the deal, Pfizer gains access to Beam’s proprietary technology that uses lipid nanoparticles to deliver genome editors that only target a single base, avoiding the undesirable side effects experienced with existing gene editing approaches. The alliance allows Pfizer to build upon its in vivo delivery expertise, following the success of its blockbuster mRNA coronavirus vaccine.